Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
2.
Brain Res ; 1008(2): 179-85, 2004 May 22.
Article in English | MEDLINE | ID: mdl-15145754

ABSTRACT

FK506 (tacrolimus), an immunosuppressant, reportedly reduces ischemic brain injury following transient middle cerebral artery occlusion (MCAO) in rats. The authors previously reported that the therapeutic window of FK506 in this model is more than 1 h, but less than 2 h. The aim of the present study is to determine whether mild hypothermia (35 degrees C) enhances the neuroprotective effects of FK506 and expands its therapeutic window. Sprague-Dawley rats were subjected to 2 h MCAO followed by 24 h reperfusion. Animals were randomly divided into four groups: (I) vehicle-treated normothermic group; (II) FK506-treated normothermic group; (III) vehicle-treated hypothermic group; (IV) FK506-treated hypothermic group. Animals received a single injection of FK506 (0.3 mg/kg) or vehicle intravenously at 2 h after ischemic induction. During ischemia, temporal muscle and rectal temperatures were maintained at 37 degrees C in the normothermic animals and at 35 degrees C in the hypothermic animals. Infarct volumes and neurological performance were evaluated at 24 h after reperfusion. The combination of FK506 and mild hypothermia significantly reduced infarct volume (cortex, -61%; striatum, -31%) and edema volume (cortex, -57%; striatum, -41%), while mild hypothermia or FK506 alone failed to improve ischemic brain damage. Furthermore, this combination also provided for the best functional outcome. These results demonstrate that the combination of FK506 and mild hypothermia significantly reduces ischemic brain damage following transient MCAO in rats, and expands the therapeutic window for FK506. This therapy may be a new approach for treatment of acute stroke.


Subject(s)
Hypothermia, Induced , Immunosuppressive Agents/therapeutic use , Ischemic Attack, Transient/drug therapy , Neuroprotective Agents , Tacrolimus/therapeutic use , Animals , Body Temperature , Brain Edema/pathology , Cerebral Infarction/pathology , Cerebrovascular Circulation , Immunosuppressive Agents/administration & dosage , Ischemic Attack, Transient/pathology , Laser-Doppler Flowmetry , Male , Rats , Rats, Sprague-Dawley , Reperfusion Injury/pathology , Tacrolimus/administration & dosage
3.
Life Sci ; 71(25): 2983-94, 2002 Nov 08.
Article in English | MEDLINE | ID: mdl-12384182

ABSTRACT

The therapeutic efficacy of ozagrel sodium (ozagrel), alone and in combination with heparin, and its therapeutic time window were studied in a photochemically induced thrombotic cerebral infarction rat model. Cerebral artery thrombosis was induced by irradiating the brain with green light through intact skull using rose bengal as the photosensitizing dye. One set of animals was treated immediately after thrombosis with (1) vehicle, (2) 10 mg/kg ozagrel in saline, intravenously (i.v.), (3) 150 U/kg unfractioned heparin, subcutaneously (s.c.), or (4) ozagrel, i.v. plus heparin, s.c. Infarct volume was significantly smaller and edema was reduced in the ozagrel-treated groups compared to the vehicle-treated group; heparin did not convey additional benefit. In another set of animals, rats were given either vehicle or 10 mg/kg ozagrel in saline, i.v., 60 min or 120 min after induction of thrombosis. Ozagrel reduced infarct volume, but its effect diminished with delayed administration. The therapeutic window was determined to be less than 60 minutes after induction of thrombosis.


Subject(s)
Cerebral Infarction/drug therapy , Fibrinolytic Agents/therapeutic use , Heparin/therapeutic use , Intracranial Thrombosis/drug therapy , Methacrylates/therapeutic use , Thromboxane-A Synthase/antagonists & inhibitors , Animals , Cerebral Arteries/pathology , Cerebral Arteries/radiation effects , Cerebral Infarction/etiology , Cerebral Infarction/pathology , Disease Models, Animal , Drug Therapy, Combination , Fibrinolytic Agents/administration & dosage , Heparin/administration & dosage , Image Processing, Computer-Assisted , Injections, Intravenous , Injections, Subcutaneous , Intracranial Thrombosis/etiology , Intracranial Thrombosis/pathology , Light , Male , Methacrylates/administration & dosage , Rats , Rats, Sprague-Dawley , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...